novavax nuvaxovid - Search News

Order byBest matchMost fresh

Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue.

· 11h

Clinical Advisor · 8h

FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid

PharmExec · 1d

FDA Grants Full Approval to Novavax’s Nuvaxovid COVID-19 Vaccine

F.D.A. Poised to Restrict Access to Covid Vaccines

The Food and Drug Administration will permit Covid vaccines for adults over 65 and those with certain medical conditions in the fall, according to new regulatory standards detailed on Tuesday by agen...

· 22h

· 1d

US FDA advisers to consider if new COVID shots should target LP.8.1 subvariant

· 23h

New Trump Vaccine Policy Limits Access To COVID Shots

FDA plans to limit COVID vaccine to only high-risk people. Who would still be eligible?

Public trust in vaccination has declined, potentially impacting other vital immunization programs.

· 7h

· 1d

New FDA rule could delay Covid vaccine rollout for healthy adults and kids

· 1d

FDA may limit future Covid-19 shots to older people and those at risk of serious infection

6hon MSN

BofA Reiterates Hold Rating on Novavax (NVAX) Stock

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of

Novavax Shares Rise on FDA License Application Approval for Nuvaxovid

The biotechnology company said the FDA approved the biologics license application for Nuvaxovid to prevent Covid-19 in adults ages 65 and up and individuals ages 12 through 64 who have at least one underlying condition that puts them at high risk for severe outcomes from the coronavirus.